, J. Thromb. Haemost

J. Schuettrumpf, R. W. Herzog, A. Schlachterman, A. Kaufhold, D. W. Stafford et al., , 2005.

, Factor IX variants improve gene therapy efficacy for hemophilia B. Blood

A. Sehgal, S. Barros, L. Ivanciu, B. Cooley, J. Qin et al., , vol.8

J. Brodsky, H. Prabhala, X. Zhang, H. Attarwala, R. Hutabarat et al., , p.9

K. Charisse, S. Kuchimanchi, M. A. Maier, and L. Nechev, An RNAi therapeutic (n=8/group). Data represent mean±SD. 18 (n=5/group) 8 weeks post-AAV administration. Data represent mean±SD, 2015.